ID CCRF-CEM/MTX R3 AC CVCL_5H82 SY CEM/MTX R3; CEM/MTXR3 DR cancercelllines; CVCL_5H82 DR Wikidata; Q54809028 RX PubMed=2754745; RX PubMed=12482398; CC Population: Caucasian. CC Selected for resistance to: ChEBI; CHEBI_44185; Methotrexate (MTX). CC Sequence variation: Gene fusion; HGNC; HGNC:13222; BCL11B + HGNC; HGNC:2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line). CC Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. CC Cell type: T-cell; CL=CL_0000084. DI NCIt; C7953; Childhood T acute lymphoblastic leukemia DI ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_0207 ! CCRF-CEM SX Female AG 3Y11M CA Cancer cell line DT Created: 14-12-15; Last updated: 19-12-24; Version: 17 // RX PubMed=2754745; DOI=10.1093/jnci/81.16.1250; RA Haber M., Reed C., Kavallaris M., Norris M.D., Stewart B.W.; RT "Resistance to drugs associated with the multidrug resistance RT phenotype following selection with high-concentration methotrexate."; RL J. Natl. Cancer Inst. 81:1250-1254(1989). // RX PubMed=12482398; DOI=10.1006/bcmd.2002.0530; RA Efferth T., Verdorfer I., Miyachi H., Sauerbrey A., Drexler H.G., RA Chitambar C.R., Haber M., Gebhart E.; RT "Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM RT leukemia cell lines."; RL Blood Cells Mol. Dis. 29:1-13(2002). //